Literature DB >> 17449532

Febrile neutropenia: transition towards a risk-directed approach.

P Anoop, M A Anjay.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2007        PMID： 17449532      PMCID： PMC2083713     

Source DB:  PubMed          Journal:  Arch Dis Child        ISSN： 0003-9888            Impact factor:   3.791


× No keyword cloud information.
  5 in total

1.  Treating low-risk febrile neutropenia: Jenny's story.

Authors:  R Phillips; R Skinner; J C Chisholm
Journal:  Arch Dis Child       Date:  2007-01       Impact factor: 3.791

2.  Oral ciprofloxacin in the management of children with cancer with lower risk febrile neutropenia.

Authors:  H Paganini; T Rodriguez-Brieshcke; P Zubizarreta; A Latella; V Firpo; L Casimir; A Armada; C Fernández; E Cáceres; R Debbag
Journal:  Cancer       Date:  2001-04-15       Impact factor: 6.860

3.  A proposed score for predicting severe infection complications in children with chemotherapy-induced febrile neutropenia.

Authors:  Patrícia Imperatriz Porto Rondinelli; Karina de Cássia Braga Ribeiro; Beatriz de Camargo
Journal:  J Pediatr Hematol Oncol       Date:  2006-10       Impact factor: 1.289

4.  Oral cefixime is similar to continued intravenous antibiotics in the empirical treatment of febrile neutropenic children with cancer.

Authors:  J L Shenep; P M Flynn; D K Baker; S V Hetherington; M M Hudson; W T Hughes; C C Patrick; P K Roberson; J T Sandlund; V M Santana; J W Sixbey; K S Slobod
Journal:  Clin Infect Dis       Date:  2000-12-08       Impact factor: 9.079

5.  Cefepime monotherapy for treatment of febrile neutropenia in children.

Authors:  Hany Ariffin; Chong Lee Ai; Chan Lee Lee; Wan Ariffin Abdullah
Journal:  J Paediatr Child Health       Date:  2006-12       Impact factor: 1.954
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.